title: B cell therapy is β-tested: Rituximab puts a pause on β-cell destruction.
authors.affiliation: Department of Medicine and Microbiology, Columbia University/Medical Center, New York, NY USA. rc645@columbia.edu
authors.forename: Raphael
authors.initials: R
authors.lastname: Clynes
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000473:pathology / Q000628:therapy; D006801:Humans; D050417:Insulin-Secreting Cells / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D016688:Mice, Inbred NOD; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab